Anthrax antigens and methods of use
View Patent ↗Anthrax antigens are provided that find use as immunogens and vaccines.
1. A dry powder immunogenic composition formulated for mucosal surface administration comprising unconjugated protective antigen (PA), chitosan, and MPL.
2. The dry powder composition of claim 1 in combination with one or more devices for administering one or more doses of said composition.
3. The dry powder composition of claim 2 , wherein said one or more doses are unit doses.
4. The dry powder composition of claim 2 , wherein the device is a single-use nasal administration device.
5. The composition of claim 1 in combination with a mucosal administration device.
6. The composition of claim 1 , wherein the composition induces anti-PA-specific IgG serum antibodies in a subject when administered to a mucosal surface of the subject.
7. A method of inducing an immune response to anthrax in a subject, comprising administering to a mucosal surface of the subject an effective amount of the composition of claim 1 .
8. The method of claim 7 , wherein replication of anthrax in the subject is inhibited.
9. The method of claim 7 , wherein anthrax exotoxin in the subject is neutralized.
10. The method of claim 7 , wherein the immune response is a protective immune response.
11. The method of claim 7 , wherein the mucosal surface is selected from the group consisting of a nasal mucosal surface and an oral mucosal surface.
12. The method of claim 7 , wherein the subject has not been exposed to anthrax.
13. The method of claim 7 , wherein the subject is infected with anthrax.
14. The method of claim 7 , wherein the subject has been exposed to anthrax.
15. The method of claim 14 , wherein the subject does not display visible signs of anorexia, lethargy and/or death as a result of exposure to anthrax.
16. The method of claim 15 , wherein the subject does not display visible signs of anorexia, lethargy and/or death up to 2 weeks after anthrax exposure.